Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.

Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18722-7. doi: 10.1073/pnas.0908853106. Epub 2009 Oct 22.

PMID:
19850877
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.

Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS.

J Natl Cancer Inst. 2008 Jan 16;100(2):140-54. doi: 10.1093/jnci/djm288. Epub 2008 Jan 8.

PMID:
18182616
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.

Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, Paquet M, Crosby K, Pomerleau V, Uetani N, Pause A.

J Med Genet. 2010 Mar;47(3):182-9. doi: 10.1136/jmg.2009.072009. Epub 2009 Oct 19.

PMID:
19843504
[PubMed - indexed for MEDLINE]
4.

Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.

Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, Merino MJ, Linehan WM, Schmidt LS.

Mol Cancer. 2010 Jun 23;9:160. doi: 10.1186/1476-4598-9-160.

PMID:
20573232
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.

Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, Li Y, Khoo SK, Huang D, Qian CN, Zhao P, Dykema K, Zhang R, Cao B, Yang XJ, Furge K, Williams BO, Teh BT.

PLoS One. 2008;3(10):e3581. doi: 10.1371/journal.pone.0003581. Epub 2008 Oct 30. Erratum in: PLoS ONE. 2008;3(11). doi: 10.1371/annotation/0f06471c-1993-4144-b785-d58924ac0b5c. PLoS ONE. 2008;3(11). doi: 10.1371/annotation/136385d5-b241-4ecc-b31a-6dea3ebf3bc4. Dykyma, Karl [corrected to Dykema, Karl].

PMID:
18974783
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.

Petersson F, Gatalica Z, Grossmann P, Perez Montiel MD, Alvarado Cabrero I, Bulimbasic S, Swatek A, Straka L, Tichy T, Hora M, Kuroda N, Legendre B, Michal M, Hes O.

Virchows Arch. 2010 Apr;456(4):355-65. doi: 10.1007/s00428-010-0898-4. Epub 2010 Mar 19.

PMID:
20300772
[PubMed - indexed for MEDLINE]
7.

Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients.

van Steensel MA, Verstraeten VL, Frank J, Kelleners-Smeets NW, Poblete-Gutiérrez P, Marcus-Soekarman D, Bladergroen RS, Steijlen PM, van Geel M.

J Invest Dermatol. 2007 Mar;127(3):588-93. Epub 2006 Nov 23.

PMID:
17124507
[PubMed - indexed for MEDLINE]
Free Article
8.

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.

Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF 3rd, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B.

Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15552-7. Epub 2006 Oct 6.

PMID:
17028174
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.

Hasumi H, Baba M, Hasumi Y, Huang Y, Oh H, Hughes RM, Klein ME, Takikita S, Nagashima K, Schmidt LS, Linehan WM.

J Natl Cancer Inst. 2012 Nov 21;104(22):1750-64. doi: 10.1093/jnci/djs418. Epub 2012 Nov 12.

PMID:
23150719
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).

Lu X, Boora U, Seabra L, Rabai EM, Fenton J, Reiman A, Nagy Z, Maher ER.

Oncogene. 2014 Feb 20;33(8):956-65. doi: 10.1038/onc.2013.27. Epub 2013 Feb 18.

PMID:
23416984
[PubMed - indexed for MEDLINE]
11.

Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.

Lu X, Wei W, Fenton J, Nahorski MS, Rabai E, Reiman A, Seabra L, Nagy Z, Latif F, Maher ER.

Mol Cancer Ther. 2011 Jan;10(1):80-9. doi: 10.1158/1535-7163.MCT-10-0628.

PMID:
21220493
[PubMed - indexed for MEDLINE]
Free Article
12.

The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development.

Baba M, Keller JR, Sun HW, Resch W, Kuchen S, Suh HC, Hasumi H, Hasumi Y, Kieffer-Kwon KR, Gonzalez CG, Hughes RM, Klein ME, Oh HF, Bible P, Southon E, Tessarollo L, Schmidt LS, Linehan WM, Casellas R.

Blood. 2012 Aug 9;120(6):1254-61. doi: 10.1182/blood-2012-02-410407. Epub 2012 Jun 18.

PMID:
22709692
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.

Schmidt LS.

Fam Cancer. 2013 Sep;12(3):357-64. doi: 10.1007/s10689-012-9574-y. Erratum in: Fam Cancer. 2013 Sep;12(3):365.

PMID:
23108783
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Birt-Hogg-Dubé syndrome, a genodermatosis that increases risk for renal carcinoma.

Schmidt LS.

Curr Mol Med. 2004 Dec;4(8):877-85.

PMID:
15579035
[PubMed - indexed for MEDLINE]
15.

High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.

Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, Merino MJ, Walther MM, Zbar B, Linehan WM.

J Natl Cancer Inst. 2005 Jun 15;97(12):931-5. Erratum in: J Natl Cancer Inst. 2005 Jul 20;97(14):1096.

PMID:
15956655
[PubMed - indexed for MEDLINE]
Free Article
16.

Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.

Houweling AC, Gijezen LM, Jonker MA, van Doorn MB, Oldenburg RA, van Spaendonck-Zwarts KY, Leter EM, van Os TA, van Grieken NC, Jaspars EH, de Jong MM, Bongers EM, Johannesma PC, Postmus PE, van Moorselaar RJ, van Waesberghe JH, Starink TM, van Steensel MA, Gille JJ, Menko FH.

Br J Cancer. 2011 Dec 6;105(12):1912-9. doi: 10.1038/bjc.2011.463.

PMID:
22146830
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.

Murakami T, Sano F, Huang Y, Komiya A, Baba M, Osada Y, Nagashima Y, Kondo K, Nakaigawa N, Miura T, Kubota Y, Yao M, Kishida T.

J Pathol. 2007 Apr;211(5):524-31.

PMID:
17323425
[PubMed - indexed for MEDLINE]
18.

[Birt-Hogg-Dubé syndrome].

Rehfeld A, van Steensel MA, Friis-Hansen L.

Ugeskr Laeger. 2010 Jul 19;172(29):2085-90. Review. Danish.

PMID:
20633341
[PubMed - indexed for MEDLINE]
19.

Inactivation of BHD in sporadic renal tumors.

Khoo SK, Kahnoski K, Sugimura J, Petillo D, Chen J, Shockley K, Ludlow J, Knapp R, Giraud S, Richard S, Nordenskjöld M, Teh BT.

Cancer Res. 2003 Aug 1;63(15):4583-7.

PMID:
12907635
[PubMed - indexed for MEDLINE]
Free Article
20.

The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, Simon MC, Henske EP.

Oncogene. 2009 Apr 2;28(13):1594-604. doi: 10.1038/onc.2009.14. Epub 2009 Feb 23.

PMID:
19234517
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk